Transplantation Tolerance: Clinical Potential of Regulatory T Cells

Overview

Journal Self Nonself

Specialty Allergy & Immunology

Date 2011 Jul 22

PMID 21776332

Citations 9

Authors

Yannick D Muller

Jorg D Seebach

Leo H Buhler

Manuel Pascual

Dela Golshayan

Affiliations

Soon will be listed here.

Abstract

The major challenge in transplantation medicine remains long-term allograft acceptance, with preserved allograft function under minimal chronic immunosuppression. To safely achieve the goal of sustained donor-specific T and B cell non-responsiveness, research efforts are now focusing on therapies based on cell subsets with regulatory properties. In particular the transfusion of human regulatory T cells (Treg) is currently being evaluated in phase I/II clinical trials for the treatment of graft versus host disease following hematopoietic stem cell transplantation, and is also under consideration for solid organ transplantation. The purpose of this review is to recapitulate current knowledge on naturally occurring as well as induced human Treg, with emphasis on their specific phenotype, suppressive function and how these cells can be manipulated in vitro and/or in vivo for therapeutic purposes in transplantation medicine. We highlight the potential but also possible limitations of Treg-based strategies to promote long-term allograft survival. It is evident that the bench-to-beside translation of these protocols still requires further understanding of Treg biology. Nevertheless, current data already suggest that Treg therapy alone will not be sufficient and needs to be combined with other immunomodulatory approaches in order to induce allograft tolerance.

Citing Articles

Matching for HLA-DR excluding diabetogenic HLA-DR3 and HLA-DR4 predicts insulin independence after pancreatic islet transplantation.

Ballou C, Barton F, Payne E, Berney T, Villard J, Meier R Front Immunol. 2023; 14:1110544.

PMID: 37026004 PMC: 10070978. DOI: 10.3389/fimmu.2023.1110544.

Tolerance in liver transplantation: Biomarkers and clinical relevance.

Baroja-Mazo A, Revilla-Nuin B, Parrilla P, Martinez-Alarcon L, Ramirez P, Pons J World J Gastroenterol. 2016; 22(34):7676-91.

PMID: 27678350 PMC: 5016367. DOI: 10.3748/wjg.v22.i34.7676.

Survival of free and encapsulated human and rat islet xenografts transplanted into the mouse bone marrow.

Meier R, Seebach J, Morel P, Mahou R, Borot S, Giovannoni L PLoS One. 2014; 9(3):e91268.

PMID: 24625569 PMC: 3953382. DOI: 10.1371/journal.pone.0091268.

Immunological challenges and therapies in xenotransplantation.

Vadori M, Cozzi E Cold Spring Harb Perspect Med. 2014; 4(4):a015578.

PMID: 24616201 PMC: 3968789. DOI: 10.1101/cshperspect.a015578.

New concepts of immune modulation in xenotransplantation.

Satyananda V, Hara H, Ezzelarab M, Phelps C, Ayares D, Cooper D Transplantation. 2013; 96(11):937-45.

PMID: 23851935 PMC: 4137477. DOI: 10.1097/TP.0b013e31829bbcb2.

References

Mangan P, Harrington L, OQuinn D, Helms W, Bullard D, Elson C . Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006; 441(7090):231-4. DOI: 10.1038/nature04754. View

Pilat N, Baranyi U, Klaus C, Jaeckel E, Mpofu N, Wrba F . Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant. 2010; 10(4):751-762. PMC: 2856406. DOI: 10.1111/j.1600-6143.2010.03018.x. View

Szymczak-Workman A, Workman C, Vignali D . Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress. J Immunol. 2009; 182(9):5188-92. PMC: 2745156. DOI: 10.4049/jimmunol.0803123. View

Allan S, Song-Zhao G, Abraham T, McMurchy A, Levings M . Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol. 2008; 38(12):3282-9. DOI: 10.1002/eji.200838373. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

Zeiser R, Negrin R . Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle. 2008; 7(4):458-62. PMC: 2886808. DOI: 10.4161/cc.7.4.5454. View

Fuchimoto Y, Huang C, Yamada K, Shimizu A, Kitamura H, Colvin R . Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest. 2000; 105(12):1779-89. PMC: 378506. DOI: 10.1172/JCI8721. View

Gokmen M, Lombardi G, Lechler R . The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol. 2008; 20(5):568-74. DOI: 10.1016/j.coi.2008.06.009. View

10.

Fantini M, Becker C, Monteleone G, Pallone F, Galle P, Neurath M . Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004; 172(9):5149-53. DOI: 10.4049/jimmunol.172.9.5149. View

11.

Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N . CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005; 202(8):1075-85. PMC: 2213209. DOI: 10.1084/jem.20051511. View

12.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R . Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110(4):1225-32. DOI: 10.1182/blood-2006-12-064527. View

13.

Zhou X, Bailey-Bucktrout S, Jeker L, Penaranda C, Martinez-Llordella M, Ashby M . Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009; 10(9):1000-7. PMC: 2729804. DOI: 10.1038/ni.1774. View

14.

Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A . Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002; 346(8):580-90. DOI: 10.1056/NEJMra011295. View

15.

Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T . Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007; 27(1):145-59. DOI: 10.1016/j.immuni.2007.04.017. View

16.

Jiang S, Golshayan D, Tsang J, Lombardi G, Lechler R . In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. Int Immunopharmacol. 2006; 6(13-14):1879-82. DOI: 10.1016/j.intimp.2006.07.025. View

17.

Sykes M . Mixed chimerism and transplant tolerance. Immunity. 2001; 14(4):417-24. DOI: 10.1016/s1074-7613(01)00122-4. View

18.

Lanzavecchia A, Sallusto F . Regulation of T cell immunity by dendritic cells. Cell. 2001; 106(3):263-6. DOI: 10.1016/s0092-8674(01)00455-x. View

19.

Wise M, Bemelman F, Cobbold S, Waldmann H . Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol. 1998; 161(11):5813-6. View

20.

Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L . The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1):20-1. DOI: 10.1038/83713. View